Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice

Gene Therapy

Volumn 15, Issue 1, 2008, Pages 54-60

  Petry, H ^a   Brooks, A ^a   Orme, A ^a   Wang, P ^a   Liu, P ^a   Xie, J ^a   Kretschmer, P ^a   Qian, H S ^a   Hermiston, T W ^a   Harkins, R N ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; LUCIFERASE; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; GENE EXPRESSION; GENE TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SKELETAL MUSCLE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; DEPENDOVIRUS; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; LUCIFERASES; MALE; MICE; MICE, INBRED C57BL; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES; VIRAL LOAD;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 37249029975     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303037     Document Type: Article

References (37)

1. Blackow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adeno-associated viruses. J Natl Cancer Inst 1968; 40: 319-327.
2. Gao GP, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004; 78: 6381-6388.
3. Grimm D, Kay MA. From virus evolution to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003; 3: 281-304.
4. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci USA 2002; 99: 11854-11859.
5. Gao GP, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005; 5: 285-297.
6. Warrington Jr HH, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 2006; 199: 571-603.
7. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJE et al Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune system. Nat Med 2006; 12 342-347.
8. McPhee SWJ, Janson CG, Li C, Samulski RJ, Camp AS, Francis JD et al Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006; 8: 577-588.
9. Jian H, Pierce GF, Ozelo MC, DePaula EV, Vargas JA, Smith P et al. Evidence of multilayer factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 2006; 14: 452-455.
10. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR et al AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Gene Therapy 2003; 101: 2963-2972.
11. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59: 406-411.
12. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure. J Virol 2000; 74: 1761-1766.
13. Chirmule N, Popert K, Magosim S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy 1999; 6: 1574-1583.
14. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR et al AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
15. Moss RB, Rodman D, Spencer LT. Repeated adeno-associated virus serotype 2 aerosol-mediated cystis fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: A multicenter, double-blind, placebo-controlled trial. Chest 2004; 125: 509-521.
16. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 1997; 71 5932-5941.
17. Chirmule N, Xiao W, Truneh A, Schnell MA, Hughes JV, Zoltick P et al Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000; 74: 2420-2425.
18. Xiao W, Chirmurle N, Schnell MA, Tazelaar J, Hughes JV, Wilson JM. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther 2000; 1 323-329.
19. Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N, Wilson JM. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001; 75: 6199-6203.
20. Ge Y, Powell S, vanRoey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 2001; 97 3733-3737.
21. Peden CS, Burger C, Muzyzka N, Mandel RJ. Circulating anti-wild-type adeno-associated virus type-2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated but not rAAV5-mediated gene transfer in the brain. J Virol 2004; 78: 6344-6359.
22. Zhang YC, Powers M, Wasserfall C, Brusko T, Song S, Flotte T et al. Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity. Gene Therapy 2004; 11: 233-240.
23. Kok MR, Voutetakis A, Yamano S, Wang J, Cotrim, A, Katano H et al. Immune responses following salivary gland administration of recombinant adeno-associated serotype 2 vectors. J Gene Med 2005; 7: 432-441.
24. Riviere C, Danos O, Douar AM. Long term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Therapy 2006; 13: 1300-1308.
25. Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing toters in SCID mice. Blood 2006; 107 1810-1817.
26. Lo WD, Qu G, Sferra TJ, Clark R, Chen R, Johnson PR. Adeno-associated virus-mediated gene transfer to the brain: Duration and modulation of expression. Hum Gene Ther 1999; 10: 201-213.
27. Jerebtsova M, Batshaw ML, Ye X. Humoral immune response to recombinant adenovirus and adeno-associated virus after in utero administration of viral vectors in mice. Pediatr Res 2002; 52 95-104.
28. Limberis MP, Wilson JM. Adeno-associated virus serotype 9 vectors transduce murine alveolar nasal epithelia and can be readministered. Proc Natl Acad Sci USA 2006; 103: 12993-12998.
29. Mastakow MY, Baer K, Symes CW, Leichtlein CB, Kotin RM, During MJ. Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J Virol 2002; 76: 8446-8454.
30. Anand V, Chirmule N, Fersh M, Maguire AM, Bennett J. Additional transduction events after subretinal readministration of recombinant adeno-associated virus. Hum Gene Ther 2000; 11: 449-457.
31. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 70: 8098-8108.
32. Chao H, Liu Y, Rabimowitz J, Li C, Samulski RJ, Welsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2: 619-623.
33. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW et al. Long term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005; 105: 1424-1430.
34. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
35. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Rucholtz W, Engleman EG. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 1999; 92: 67-75.
36. Szymanski P, Kretschmer PJ, Bauzon MM, Jin F, Qian HS, Rubanyi GM et al. Development and validation of a robust and versatile one-plasmid regulated gene expression system. Mol Ther 2007; 15: 1340-1347.
37. Auricchio A, Hildinger M, O'Connor E, Gao GP, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 2001; 12: 71-76.